Who is sponsoring NCT04156113?

NCT04156113 is sponsored by Eastern Mediterranean University.

What drugs are being tested in NCT04156113?

Interventions in NCT04156113: Yo-Yo intermittent recovery test (level 1).

What condition does NCT04156113 study?

NCT04156113 studies Uncoupling Protein-1, Polymorphism, Restriction Fragment Length, Irisin.

Is NCT04156113 still recruiting?

NCT04156113 is currently completed. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT04156113

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of an Exercise on Serum Uncoupling Protein-1 Level and the Role of Uncoupling Protein-1-3826 A/G Polymorphism

Completed NA Last updated 9 September 2020

What this trial tests

NA trial testing Yo-Yo intermittent recovery test (level 1) in Uncoupling Protein-1 in 86 participants. Completed in 7 September 2020.

Timeline

11 November 2019

Primary endpoint
2 September 2020

7 September 2020

Quick facts

Lead sponsor	Eastern Mediterranean University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	86
Start date	11 November 2019
Primary completion	2 September 2020
Estimated completion	7 September 2020
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Yo-Yo intermittent recovery test (level 1)

Conditions studied

Uncoupling Protein-1 — all drugs for Uncoupling Protein-1 →
Polymorphism, Restriction Fragment Length — all drugs for Polymorphism, Restriction Fragment Length →
Irisin — all drugs for Irisin →

Sponsor

Eastern Mediterranean University

Who can join

Adults 18 to 35, male only, with Uncoupling Protein-1 or Polymorphism, Restriction Fragment Length. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine the effect of an acute maximal exercise on serum uncoupling protein-1, irisin, interleukin 6 levels, and on blood lipid and lipoprotein concentrations. This study also evaluates the role of uncoupling protein-1-3826 A/G polymorphism on this eventual effect. Therefore, this study hypothesizes that: H01: Sedentary people and athletes' serum uncoupling protein 1, irisin, and interleukine 6 levels are different before and after an acute maximal exercise. H02: Sedentary people and athletes' basal serum uncoupling protein 1 levels are associated with uncoupling protein 1-3826 A/G polymorphism. H03: Uncoupling protein 1-3826 A/G polymorphism has a modifying role in the effect of maximal exercise on serum uncoupling protein 1 levels. H04: Sedentary people and athletes' basal serum lipid and lipoprotein levels are associated with uncoupling protein 1-3826 A/G polymorphism. H05: Uncoupling protein 1-3826 A / G polymorphism has a modifying role in the effect of maximal exercise on serum lipid and lipoprotein levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Eastern Mediterranean University trials

Trials by the same sponsor.

NCT07462039 — Effect of Virtual Reality on Pain and Anxiety During Pap Smear Testing · NA · not yet recruiting
NCT07328750 — Dynamic Q Angle and Core Endurance in Adolescent Athletes With Patellofemoral Pain Syndrome · recruiting
NCT07311005 — NURSE - LED DIGITAL EDUCATION AND BIGOREXIA · NA · enrolling by invitation
NCT07077993 — "Muscle Strength, Balance, and Core Endurance in Elite Adolescent Rowers: A Cross-Sectional Study" · completed
NCT06953037 — Effects of Acupressure Applied Before Cesarean Delivery on Anxiety, Physiological Parameters and Fetal Heart Rate · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04156113 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Mediterranean University
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing